AGN Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands andbest-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.
Company profile
Ticker
AGN
Exchange
Website
CEO
Brenton L. Saunders
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Actavis Ltd, Actavis plc
SEC CIK
Corporate docs
Subsidiaries
AGN International Inc. • AGN Kythera, L.P. • AGN Labs LLC • AGN LLC • AGN Sundry LLC • Akarna Therapeutics, Limited • Allergan WC 1 S.a r.l. • Allergan (Chengdu) Medical Aesthetics Clinic Co., Ltd. • Allergan (Thailand) Limited • Allergan AG ...
AGN stock data
()
Calendar
7 May 20
28 Sep 21
31 Dec 21
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | No | 0 | 16,532 | 0 | 0 |
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | Yes | No | 0 | 9,538 | 0 | 16,542 |
| 8 May 20 | Coughlin Christopher J | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | Yes | No | 0 | 471 | 0 | 26,080 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | No | 70.79 | 9,446 | 668.68K | 0 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | No | 73.14 | 3,691 | 269.96K | 0 |
| 8 May 20 | Coughlin Christopher J | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | No | 90.22 | 2,790 | 251.71K | 0 |
| 8 May 20 | William Meury | RSU | Sale back to company | Dispose D | No | No | 0 | 25,201 | 0 | 0 |
| 8 May 20 | William Meury | Ordinary Shares, par value $0.0001 | Sale back to company | Dispose D | No | No | 0 | 7,434 | 0 | 0 |
| 8 May 20 | William Meury | Performance Stock Units Ordinary Shares | Sale back to company | Dispose D | No | No | 0 | 26,506 | 0 | 0 |
| 8 May 20 | William Meury | Stock Options Ordinary Shares | Sale back to company | Dispose D | No | No | 196.16 | 12,304 | 2.41M | 0 |
Institutional ownership Q2 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
5.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 3 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 16.99M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| GIC Private | 16.99M | $0 |
| IFP Advisors | 0 | $0 |
Financial report summary
?Competition
Akorn • TherapeuticsMD • AMGEN • Hologic • Veru • Vivus • Royalty Pharma • Palatin • Integra Lifesciences • IRIDEXContent analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
alpha, API, argument, Asia, AstraZeneca, autoimmune, behavior, biodegradable, broadest, built, buyer, Cadila, certainty, chain, composition, confirm, confirming, contamination, continent, Coolsculpting, CoolTone, Cream, cystic, declare, deliver, detailing, discontinuation, discontinued, distancing, Durysta, electronic, enrolling, environment, enzyme, Esthetique, evolve, exocrine, experienced, Gedeon, genericization, glaucoma, globe, half, home, hypertension, inability, indirectly, inhibitor, innovation, insufficiency, intracameral, intraocular, IOP, Ireland, Lab, Lazeo, LIBOR, lifetime, local, logistical, losing, medial, minute, mitigate, Nestle, OAG, ocular, OHT, outbreak, Pacific, pancreatic, pandemic, patient, pressure, rebate, recession, recovery, relationship, remotely, reply, Richter, satisfaction, Science, shelter, spent, spread, strain, susceptible, suspended, temporarily, Ubrelvy, unemployment, Viokace, Vital
Removed:
absence, acceleration, acid, add, adjunctive, advancement, affirming, Akorn, Akron, Apotex, appellate, applied, Argentum, asserting, authorize, automatically, back, binding, BioMed, Biomedical, Body, bound, buy, calculate, calculated, capitalized, capitalizing, Center, centralized, certiorari, chosen, clarify, cloud, collateralization, collateralized, commonly, computing, concurrently, Contouring, contractually, conversion, correct, corrected, Corrupt, cumulative, delaying, Delzicol, denial, denying, Depressive, dermatology, determining, Deva, disgorgement, Disorder, dozen, Easement, enablement, enacted, enforceable, Envy, equaled, equipment, equitable, error, established, estate, Europe, exemption, exercised, expedient, explicitly, Famy, fiscal, fleet, fourth, Framework, gamma, GILTI, ground, Harbor, HD, higher, hosted, immunity, implementation, implicit, implicitly, improper, incorrectly, India, Influenced, InnoPharma, institute, instrument, intent, invalidity, inventorship, issuing, joinder, LA, land, lease, leasing, Legacy, legally, lessee, lessor, Lidoderm, LifeCell, limit, Low, mandatorily, mandatory, MDD, modified, modify, noncancelable, notification, offsetting, older, opening, option, orphan, ownership, package, pattern, Pennsylvania, pension, permission, pertaining, Pharmacal, pivotal, plant, Plastic, postretirement, practical, preferred, prepaid, preventing, privately, pronouncement, prospectively, purpose, qualify, Racketeer, rapastinel, rating, reaching, real, receptor, reclassification, reclassify, recognition, redeemed, refinancing, released, remove, renew, renewal, rental, Replacement, represented, requiring, residual, restitution, resurfacing, retinoic, retired, retrospective, retrospectively, revaluation, reversing, RORyt, ROU, SA, scaling, shortened, skin, Slayback, software, sovereign, standalone, statutory, stranded, substantive, substitute, Subtopic, suit, supplier, Surgery, suspension, Targeted, Taxed, TCJA, terminate, Therapy, threshold, topline, treble, tribal, TWi, Ubrogepant, unrelated, updated, USD, vendor, VI, Vitae, withdraw, withdrew, writ
Financial reports
10-Q
2020 Q1
Quarterly report
7 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
18 Feb 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
14 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q/A
2018 Q1
Quarterly report (amended)
25 May 18
Current reports
8-K
Material Modifications to Rights of Security Holders
14 May 20
8-K
AbbVie Inc. Completes Acquisition of Allergan plc
8 May 20
8-K
Announcement relating to the outcome of the Court Sanction Hearing
6 May 20
8-K
Temporary Suspension of Trading Under Registrant's Employee Benefit Plans
21 Apr 20
8-K
AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
17 Mar 20
8-K
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
3 Mar 20
8-K
Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results
10 Feb 20
8-K
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
27 Jan 20
8-K
Third Quarter 2019 Financial Results—Frequently Asked Questions
5 Nov 19
8-K
Allergan Reports Third Quarter 2019 Financial Results
5 Nov 19
Registration and prospectus
15-12B
Securities registration termination
21 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
POS AM
Prospectus update (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
14 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
3 Oct 19
DEFA14A
Additional proxy soliciting materials
27 Sep 19
DEFM14A
Proxy related to merger
16 Sep 19
DEFA14A
Additional proxy soliciting materials
10 Sep 19
PREM14A
Preliminary proxy related to merger
12 Aug 19
DEFA14A
Additional proxy soliciting materials
12 Jul 19
DEFA14A
Additional proxy soliciting materials
8 Jul 19
DEFA14A
Additional proxy soliciting materials
1 Jul 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
DEFA14A
Additional proxy soliciting materials
28 Jun 19
Other
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
EFFECT
Notice of effectiveness
19 May 20
SD
Conflict minerals disclosure
23 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
30 May 17
UPLOAD
Letter from SEC
22 Feb 17
CORRESP
Correspondence with SEC
13 Feb 17
UPLOAD
Letter from SEC
6 Feb 17
Ownership
4
Allergan / Nesli Basgoz ownership change
12 May 20
4
Allergan / Joseph H Boccuzi ownership change
12 May 20
4
Allergan / ROBERT J HUGIN ownership change
11 May 20
4
Allergan / CHRIS W BODINE ownership change
11 May 20
4
Allergan / James DArecca ownership change
11 May 20
4
Allergan / Adriane M Brown ownership change
11 May 20
4
Allergan / A Robert D Bailey ownership change
11 May 20
4
Allergan / THOMAS C FREYMAN ownership change
11 May 20
4
Allergan / MATTHEW M WALSH ownership change
11 May 20
4
Allergan / CAROL ANTHONY DAVIDSON ownership change
11 May 20
Patents
APP
Utility
Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
23 Sep 21
Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations.
APP
Utility
Formation of Bone
11 Feb 21
Compositions and methods for inducing or promoting repair of a bone fracture.
APP
Utility
Method for Stabilizing a Toxin
11 Feb 21
Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
GRANT
Utility
Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
9 Feb 21
Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided.
GRANT
Utility
Androgen composition for treating an ophthalmic condition
2 Feb 21
The disclosure provides compositions for treating an ocular condition.
Reddit threads
Weekend Discussion thread for the Weekend of Apr-30-2021
30 Apr 21
Daily General Discussion and spitballin thread - April 09, 2021
9 Apr 21
Vlad's testimony in a nutshell
19 Feb 21
stocks I like - for the hedge funds buying tech to track this
19 Feb 21
PLTR 440k YOLO - Holding since November and now loaded up on LEAPS 🚀
19 Feb 21
Palantir (PLTR) & What It Does
19 Feb 21
PLTR up 7% premarket. Also, the number of wsb comments on a stock relative to GME comments is apparently an analyst metric. 🍌
19 Feb 21
How I pick a stock that I think will explode
12 Feb 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - January 31, 2021
30 Jan 21
People are evoking emotions to affect your decisions
29 Jan 21